anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Individuals with severe paralysis have intact brain function but are unable to move due to injury or disease affecting the spinal cord, nerves or muscles. Brain-machine interface (BMI) technology is based on the finding that with intact brain function, neural (nerve) signals are generated even though they do not reach the arms, hands and legs. By placing (implanting) sensors on the surface of the brain, individuals can be trained to send neural signals which are interpreted by a computer and translated to movement which can then be used to control a variety of devices or computer displays. Using neural activity to control an external device is referred to as a brain-machine interface (BMI) technology. In addition, areas of the brain that are involved in interpreting sensations from the arms, hands and legs remain functional after injury. It is therefore possible to send tiny electrical pulses through implanted arrays to mimic sensory input that would normally come from the arms, hands and legs. The investigators refer to this as "microstimulation."
Provided herein are methods for a novel combination therapy for treating a glutamine-addicted cancer in a subject in need thereof, which comprises the administration of a glutaminase antagonist and a pro-apoptotic compound. Specific glutaminase antagonists and pro-apoptotic compounds are provided. In some embodiments, the glutaminase antagonist is 6-diazo-5-oxo-1-norleucine (DON) and the pro-apoptotic compound is a Bcl-2 family member antagonist. In some embodiments, the pro-apoptotic compound is obatoclax mesylate, navitoclax, or fenretinide. In some embodiments, the glutamine-addicted cancer is a cancer in which Myc is deregulated. In some embodiments, the cancer is a pediatric cancer.
A composition for treating wounds is provided. The composition includes an antimicrobial component, an emulsifying agent, and a cidatrope component. The antimicrobial component can be selected from octenidine, poly(hexamethylene biguanide), a quaternary ammonium antimicrobial compound, and salts thereof. The cidatrope is not an alpha-hydroxy acid, a beta-hydroxy acid, a chelating agent, a (C1-C4)alkyl carboxylic acid, a (C6-C12)aryl carboxylic acid, a (C6-C12)aralkyl carboxylic acid, a (C6-C12)alkaryl carboxylic acid, a phenolic compound, a (C1-C10)monohydric alkyl alcohol, or an ether glycol. In certain embodiments, the composition can be substantially free of water and C2-C5 lower alcohols. In certain embodiments, the composition further can comprise water. Methods of using the composition are also provided.
PURPOSE: A pathologic complete response (pCR) to neoadjuvant chemoradiotherapy (nCRT) is seen in up to 40% of the patients with esophageal squamous cell carcinoma (ESCC). No nomogram has been constructed for the prediction of pCR for patients whose primary chemotherapy was a taxane-based regimen. The aim is to identify characteristics associated with a pCR through analyzing multiple pre- and post-nCRT variables and to develop a nomogram for the prediction of pCR for these patients by integrating clinicopathological characteristics and hematological biomarkers.
MATERIALS AND METHODS: We analyzed 293 patients with ESCC who underwent nCRT followed by esophagectomy. Clinicopathological factors, hematological parameters before nCRT, and hematotoxicity during nCRT were collected. Univariate and multivariate logistic regression analyses were performed to identify predictive factors for pCR. A nomogram model was built and evaluated for both discrimination and calibration.
RESULTS: After surgery, 37.88% of the study patients achieved pCR. Six variables were included in the nomogram: sex, cN stage, chemotherapy regimen, duration of nCRT, pre-nCRT neutrophil-to-lymphocyte ratio (NLR), and pre-nCRT platelet-to-lymphocyte ratio (PLR). The nomogram indicated good accuracy and consistency in predicting pCR, with a C-index of 0.743 (95% confidence interval: 0.686, 0.800) and a p value of 0.600 (>0.05) in the Hosmer-Lemeshow goodness-of-fit test.
CONCLUSIONS: Female, earlier cN stage, duration of nCRT (< 62 days), chemotherapy regimen of taxane plus platinum, pre-nCRT NLR (≥2.199), and pre-nCRT PLR (≥99.302) were significantly associated with a higher pCR in ESCC patients whose primary chemotherapy was a taxane-based regimen for nCRT. A nomogram was developed and internally validated, showing good accuracy and consistency.
Use of a colloid suspension of mineral fillers, which may be prepd. by a sol-gel process, as a cosmetic compsn. for forming a mineral film on the skin, hair or nails after evapn. of the liq. medium from the suspension is claimed. Also claimed is a process for cosmetic treatment of the skin, hair and/or nails, comprising applying a compsn. as above to form a metal oxide or salt film after evapn. of the liq. medium.
Along with hyperglycemia, the presence of obesity and dyslipidemia, risk factors associated with the natural onset of diabetes mellitus type 2, could possibly explain the high susceptibility of the glucose intolerance to cardiovascular disease. Dyslipidemia commonly linked to glucose intolerance is characterized by hypertriglyceridemia, low HDL-C and in spite of the LDL-C being apparently normal or slightly elevated, there is presence of small dense LDL. Formulated in the laboratory, an artificial lipid nanoemulsion marked with both 14C-cholesterol ester and 3H-cholesterol with lipid composition similar to LDL allows study the plasma kinetics of the two forms of cholesterol (free and esterified. The nanoemulsion mimics the natural LDL, but is prepared without protein. In contact with the bloodstream, the nanoemulsion acquires apolipoproteins, apo E preferentially, allowing it to be recognized and removed from plasma by LDL receptor. The application of this nanoemulsion was shown to be technically safe, appropriate and simple to be used in humans in order to understand the role of dyslipidemia in the atherogenic process.
NEW MATERIAL:A compound shown by the formula. USE:An antitumoragent, and an antibacterial agent. PREPARATION:For example, Actinomadura roseoviolacea IR20 (FERM P-7138) belonging to the genus Actinomadura, capable of producing anthracycline compound 20X2, is inoculated into a medium containing polypeptone, molasses, meat extract, etc., and cultivated to give a yeast culture. Then, it is cultivated in a medium consisting of an aqueous solution containing glucose, soybean flour, dried yeast, calcium carbonate, etc., the culture solution is filtered, and the mold is separated from the filtrate. The filtrate is passed through a column of an adsorbing resin. R20X2 is adsorbed on it, eluted with methanol, the elute is concentrated, and purified to give a compound shown by the formula.
The present invention discloses a method for preparing degradable biologically active artificial bones. A liquid phase deposition reaction is used under an acid condition to prepare a superfine high-purity CPC solid phase component, and a high temperature solid-solid phase reaction is used to generate a CPC solid phase system. BMP is compounded into CPC by a liquid phase compounded method to protect the bioactivity of the BMP and to make the BMP homogeneously distributed into the solidified CPC and slowly released with the formation of new bones and the degradation of materials after being transplanted in vivo. The observation of a scanning electron microscope discovers that holes between the crystals of the materials are enlarged after the BMP is compounded, which is favorable for the growth of the new bones and performs the function of promoting the degradation of the materials. Because the CPC is converted into biologically active materials with the strong function of inducing bone formation from inorganic materials by the BMP, the local metabolism of an organism is activated and characterized in the formation of the new bones. Experimental observation proves that the speed of degradation is obviously accelerated and shows that the present invention has excellent clinical application prospect. The present invention can be used for treating clinical fracture, bone disconnection, bone defect, osteoporosis, etc. and can also be used in the veterinary medicine accompanied with the treatment of bone fracture.
The purpose of this study is to evaluate the efficacy of humanized monoclonal anti-IL5 antibody, SCH 55700 in reducing peripheral blood eosinophilia in patients with either hypereosinophilic syndrome or eosinophilic gastroenteritis. Patients with hypereosinophilic syndrome refractory to or intolerant of therapy with conventional therapy (steroids, hydroxyurea and interferon alpha) will be admitted on this protocol. Additionally, subjects with eosinophilic gastroenteritis refractory or intolerant to conventional therapy (systemic glucocorticoids) will be admitted on this protocol. A thorough clinical evaluation will be performed with emphasis on potential sequelae of eosinophil-mediated tissue damage. A baseline bone marrow will be obtained to exclude neoplasia and to assess the degree and nature of eosinophilipoiesis. Blood cells and/or serum will also be collected to provide reagents (such as DNA, RNA, and specific antibodies) for use in the laboratory to address issues related to the immunologic basis of FHES and GE as well as their pathogenesis and treatment. Following intravenous administration of a single 1 mg/kg dose of the humanized monoclonal anti-IL5 antibody, SCH 55700, patients will be followed in an inpatient setting for a minimum of 72 hours for monitoring of adverse effects secondary to the infusion. Followup visits will be scheduled monthly for 1 year or until the peripheral eosinophil count returns to baseline. Patients showing a reduction in eosinophilia and evidence of clinical improvement will be eligible to receive 5 additional doses of 1 mg/kg of SCH 55700 at monthly intervals.
OBJECTIVE: The inconsistency in conclusions from early observational studies has sparked our interest in elucidating the relationship between lipid levels and susceptibility to hyperemesis gravidarum (HG). This study wishes to employed Mendelian randomization analysis to investigate the causal relationship between low-density lipoprotein cholesterol (LDL-C) and HG.
METHODS: We employed Tow-Sample MR analysis to investigate the causal associations between LDL-C and HG. Specific variables were selected from GWAS database for MR analysis, using single nucleotide polymorphisms (SNPs) as our instruments. The threshold for significant SNPs as genetic instruments has been set at 5 × 10-8. F-statistic was employed to validate the strength of exposure instruments. The causality was mainly evaluated by Inverse Variance Weighted method (IVW). To address potential bias from the selection of genetic variants with pleiotropic effects, sensitivity analysis was performed by Cochrane Q-test, MR Egger, weighted median, MR-PRESSO and Leave-one-out methods. To validate the directionality of causal relationships, we employed Steiger test to filter SNPs. At last, we conducted reverse MR to exclude the causal impact of HG on LDL-C levels.
RESULTS: Our MR results identified the effect of genetically predicted increased LDL-C levels on increased genetic susceptibility to HG (OR:1.30; 95%CI:1.03-1.65; p = 0.028). In reverse MR analyses, no evidence was found for causal effect of HG on LDL-C levels (OR:1.00; 95%CI:1.00-1.01; p = 0.163). Sensitivity analyses were used to confirm reliability.
CONCLUSION: This study may have provided evidence of genetically predicted increased LDL-C levels on increased genetic susceptibility to HG. Appropriate lowering LDL-C levels may serve as a preventive and treatment measure for HG.
<P>PROBLEM TO BE SOLVED: To provide an easy-to-browse medical report even when a plurality of views are included in the medical report.  <P>SOLUTION: A report editing screen 47 of a report creation system is provided with input areas for inputting a plurality of views. Each input are is composed of input fields 49a, 50a for inputting observation records and input fields 49b, 50b for inputting names of diagnosed diseases, respectively. The report creation terminal is provided with a table in which the names of diagnosed diseases are associated with importance. When the views are input, the report creation terminal reads the names of diagnosed diseases to read the importance corresponding to the names of diagnosed diseases, and associates the views with the importance. A report in which the views are associated with the importance is displayed on a report display screen 61 of a report browsing terminal. On the report display screen 61, the views are sorted according to the importance, and views with high importance are displayed in a higher position.  <P>COPYRIGHT: (C)2010,JPO&INPIT
PROBLEM TO BE SOLVED: To obtain a cholesterol lowering agent and a cholesterol lowering food capable of reducing the blood serum cholesterol. SOLUTION: This cholesterol lowering agent comprises a shell fine powder of Paralithodes camtschatica having <=50μm particle size of median diameter. The fine shell powder of the Paralithodes camtschatica is obtained by drying a shell prepared at the time of shucking processing of the crab, powdering the resultant shell with a pulverizer, further pulverizing the resultant powder with a ball mill and providing a powder having <=50μm median diameter. The amount of the cholesterol lowering agent added into a food is 2-6% based on the total amount of the food (e.g. a fish meat processed product, a livestock meat processed product, pastas, noodles or shao-mai). No sandiness is caused in the food even when adding the cholesterol lowering agent thereto and application thereof to the food can readily be made.  Since the treatment for converting the crab shell into chitin-chitosan with an acid or an alkali is not required, the shell fine powder is industrially advantageous.
An artificial agent based cognitive operating room system and a method thereof providing automated assistance for a surgical procedure are disclosed. Data related to the surgical procedure from multiple data sources is fused based on a current context. The data includes medical images of a patient acquired using one or more medical imaging modalities. Real-time quantification of patient measurements based on the data from the multiple data sources is performed based on the current context. Short-term predictions in the surgical procedure are forecasted based on the current context, the fused data, and the real-time quantification of the patient measurements. Suggestions for next steps in the surgical procedure and relevant information in the fused data are determined based on the current context and the short-term predictions. The suggestions for the next steps and the relevant information in the fused data are presented to an operator.
A nasal delivery device for and a method of delivering substance to a nasal cavity of a subject, the delivery device comprising: a nozzle through which substance is in use delivered to the nasal cavity; and a delivery unit for delivering substance through the nozzle. The devices may include a cuff for insertion in the nose. The cuff may inflate in response to the exhalation of the user and produce a fluid tight seal in the nasal cavity. The cuff may have a particular size and shape in order direct a medicament to a particular part of the nasal canal such as the olfactory region in order to by-pass the blood brain barrier. The medicament release may be timed to coincide or follow the release of a separate gas flow intended to entrain the medicament. The devices may be provided with a mouthpiece such that medicament release is timed to coincide with exhalation which has the effect of closing the oropharyngeal velum.
<P>PROBLEM TO BE SOLVED: To provide a means for improving storage stability of a prunus spp. extract in a prunus spp. extract-containing composition to keep its antioxidative potency, and to keep the good smell of the prunus spp. extract-containing composition.  <P>SOLUTION: The prunus spp. extract stabilizer includes a rose extract as an active ingredient. There are also provided a method of stabilizing a prunus spp. extract by adding the prunus spp. extract stabilizing agent to the composition containing the prunus spp. extract, and a prunus spp. extract-containing external skin care preparation composition in which the prunus spp. extract stabilizing agent is further added.  <P>COPYRIGHT: (C)2011,JPO&INPIT
NSAIDs are mainly used drugs in rheumatic disease and cardiologic disease. However the gastroenterological lesions prevent patients get benefits from continuing taking NSAIDs. HP is another important factor that increase gastroenterological lesions. Both HP and NSAIDs increase risk of peptic ulcers, however, no exact relation between these two factors has been found. It is important to evaluate the protective effects of eradication of HP in NSAIDs-taking patients. In many countries ,PPI is recommended as maintain treatment in NSAIDs-taking patients to prevent gastroenterological lesions. A multicenter, open-label, randomized, parallel-group study is needed to prove the effects of Teprenone as a replacer of PPI in maintain treatment.On the other hand, Small-intestinal mucosal injuries induced by non-steroidal anti-inflammatory drugs (NSAIDs) are common. However, there are still no effective and reliable interventions established. Geranylgeranylacetone (GGA) is a mucosal protective agent, so we develop an additional trail to clarify the discrepancies of GGA effects on NSAIDs-induced small-intestinal mucosal injuries.
An ingestible formulation for a malodor eliminator for animals that works systemically and comprises a formulation of a chlorophyll derivative combined with  Spirulina  and alfalfa wherein the chlorophyll derivative is at least 90 percent of the formulation is presented. In the preferred embodiment, the chlorophyll derivative is chlorophyllin. The formulation may be a capsule, liquid, tablet, or gelcap when in its usable form with the preferred embodiment being in a capsule formulation. When produced in tablet form, the formulation may also include a tableting agent. The formulation has a dissolution time generally sufficient to allow the formulation to pass an animal's stomach before beginning to breakdown. The formulation is dose dependent and will vary depending on the size of the animal to which it is given.
Patients receive androgen receptor antagonist ARN-509 and abiraterone acetate PO daily, prednisone PO BID and indomethacin PO TID. Patients also receive degarelix SC on day 1 and every 4 weeks for 3 doses. Treatment continues for up to 12 weeks in the absence of disease progression or unacceptable toxicity. Patients undergo prostatectomy on day 85.
The aim of this multicenter study was to evaluate the effectiveness and safety of electrochemotherapy (ECT) for the treatment of mucosal tumors in the head and neck. A total of 71 patients with 84 nodules of different histologies in the oral cavity, pharynx and larynx treated by ECT were evaluated. The data were collected from the InspECT database from 10 participating centers throughout Europe. Primary and recurrent/secondary tumors of different histologies were treated. The overall response rate was 65 %, with a 33 % complete response rate with limited side effects. The response rates of the primary and secondary tumors were not different. However, smaller tumors responded better than tumors larger than 3 cm in diameter. Furthermore, the tumors that were treated with curative intent responded significantly better than those treated with palliative intent. This study demonstrated the feasibility, safety and effectiveness of ECT in a larger cohort of patients with mucosal lesions in the head and neck region. Based on the available data, ECT can be used for the treatment of recurrent and, in some cases, primary mucosal tumors located in the oral cavity, larynx, and pharynx. A better response was obtained in patients with smaller primary tumors treated with curative intent.
The most important therapeutic action of atropine is the inhibition of smooth muscle and glands innervated by postganglionic cholinergic nerves. It also has central nervous system activity, which may be stimulating or depressing depending upon the dose.  
Following the administration of usual clinical doses, atropine produces stimulation of the medulla and higher cerebral centers. This effect is manifested by mild central vagal excitation and moderate respiratory stimulation. Atropine sulfate also acts peripherally as a competitive antagonist of the muscarinic actions of acetylcholine. It does not prevent the release of acetylcholine but antagonizes the effect of acetylcholine on the effector cells.  
These actions include vasodilation, drying of the mouth, an increase in the pulse rate, inhibition of contractions of the gastrointestinal tract, ureter, and bladder, and reduction of salivary, bronchial, gastric and sweat gland secretions. Following clinical and larger doses, atropine sulfate causes dilation of the pupils and paralysis of accommodation and, in narrow-angle glaucoma, can increase intraocular pressure.
BACKGROUND: The Manchester Intermittent versus Daily Diet App Study (MIDDAS) tested the feasibility and potential efficacy of two remotely delivered low-energy diet (LED) programmes (800 kcal/day) to support weight loss and remission of type 2 diabetes: continuous [CLED] (8 weeks of daily LED) and intermittent [ILED] (2 days of LED/week for 28 weeks). Understanding participant experiences can help us to understand the acceptability of LED programmes to people with type 2 diabetes, informing future programme development and implementation.
METHODS: Twenty participants (10 CLED; 10 ILED) took part in interviews conducted at the end of the active weight loss phase (CLED week 12, ILED week 28). Interviews were transcribed and analysed thematically using the template analysis approach, with an a priori focus on acceptability. Four themes are presented: prospective acceptability, intervention coherence and perceived effectiveness, opportunity costs and self-efficacy.
RESULTS: Both remotely supported CLED and ILED interventions appeared acceptable to participants. CLED participants found the rapid initial weight loss phase comparatively easy and highly motivating but expressed more concerns around weight maintenance. ILED participants found the more gradual weight loss initially frustrating but expressed greater confidence in their longer-term adherence. The importance of continued individualised support from healthcare professionals was emphasised, and evidence of weight loss and improvement in other medical markers through monitoring via the mobile phone app was useful.
CONCLUSION: Different approaches to remotely delivered LEDs appear acceptable; therefore asking patients which approach may be more acceptable to them may be a useful way to offer individualised and tailored support.